These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 29374719)

  • 1. Phase II Study of S-1 plus Trastuzumab for HER2-positive Metastatic Breast Cancer (GBCCSG-01).
    Fujii T; Horiguchi J; Yanagita Y; Koibuchi Y; Ikeda F; Uchida N; Kimura M;
    Anticancer Res; 2018 Feb; 38(2):905-909. PubMed ID: 29374719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer.
    Takashima T; Nakayama T; Yoshidome K; Kawajiri H; Kamigaki S; Tsurutani J; Arai T; Ito T; Komoike Y; Doi T; Masuda N; Miyauchi K; Miyoshi Y; Sakamoto J; Morita S; Taguchi T
    Anticancer Res; 2014 Jul; 34(7):3583-8. PubMed ID: 24982373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer.
    Chua C; Tan IB; Yamada Y; Rha SY; Yong WP; Ong WS; Tham CK; Ng M; Tai DW; Iwasa S; Lim HY; Choo SP
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):397-408. PubMed ID: 26099969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab Emtansine (T-DM1) Plus S-1 in Patients with Trastuzumab-Pretreated HER2-Positive Advanced or Metastatic Breast Cancer: A Phase Ib Study.
    Kojima Y; Yoshie R; Kawamoto H; Shimo A; Uejima T; Iwatani T; Motoyoshi A; Kanemaki Y; Boku N; Tsugawa K
    Oncology; 2019; 96(6):309-317. PubMed ID: 30893699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.
    Chan A; Conte PF; Petruzelka L; Tubiana-Mathieu N; Ganju V; Llombart A; Espie M; Majois F; Gil MG; Vaissiere N; Villanova G
    Anticancer Res; 2013 Jun; 33(6):2657-64. PubMed ID: 23749924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06).
    Kimura Y; Fujii M; Masuishi T; Nishikawa K; Kunisaki C; Matsusaka S; Segawa Y; Nakamura M; Sasaki K; Nagao N; Hatachi Y; Yuasa Y; Asami S; Takeuchi M; Furukawa H; Nakajima T;
    Gastric Cancer; 2018 May; 21(3):421-427. PubMed ID: 28936560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
    Farhat F; Kattan JG; Ghosn M
    Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer.
    Kataoka H; Mori Y; Shimura T; Nishie H; Natsume M; Mochizuki H; Hirata Y; Sobue S; Mizushima T; Sano H; Mizuno Y; Nakamura M; Hirano A; Tsuchida K; Adachi K; Seno K; Kitagawa M; Kawai T; Joh T
    Cancer Chemother Pharmacol; 2016 May; 77(5):957-62. PubMed ID: 27002325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer.
    Nakayama T; Morita S; Takashima T; Kamigaki S; Yoshidome K; Ito T; Taguchi T; Sakamoto J; Noguchi S
    Anticancer Res; 2011 Sep; 31(9):3035-9. PubMed ID: 21868555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study).
    Kagawa S; Muraoka A; Kambara T; Nakayama H; Hamano R; Tanaka N; Noma K; Tanakaya K; Kishimoto H; Shigeyasu K; Kuroda S; Kikuchi S; Kuwada K; Nishizaki M; Shirakawa Y; Fujiwara T
    Cancer Chemother Pharmacol; 2018 Feb; 81(2):387-392. PubMed ID: 29290024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
    de Azambuja E; Holmes AP; Piccart-Gebhart M; Holmes E; Di Cosimo S; Swaby RF; Untch M; Jackisch C; Lang I; Smith I; Boyle F; Xu B; Barrios CH; Perez EA; Azim HA; Kim SB; Kuemmel S; Huang CS; Vuylsteke P; Hsieh RK; Gorbunova V; Eniu A; Dreosti L; Tavartkiladze N; Gelber RD; Eidtmann H; Baselga J
    Lancet Oncol; 2014 Sep; 15(10):1137-46. PubMed ID: 25130998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2, multicenter, single-arm study of eribulin mesylate with trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer.
    Wilks S; Puhalla S; O'Shaughnessy J; Schwartzberg L; Berrak E; Song J; Cox D; Vahdat L
    Clin Breast Cancer; 2014 Dec; 14(6):405-12. PubMed ID: 25024001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer.
    Sakaguchi K; Nakatsukasa K; Koyama H; Kato M; Sakuyama A; Matsuda T; Tsunoda N; Fujiwara I; Yamaguchi M; Tanaka H; Onishi K; Onishi M; Yoshino Y; Kikuchi T; Taguchi T
    Anticancer Res; 2018 Jul; 38(7):4073-4081. PubMed ID: 29970533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer.
    Jhaveri K; Wang R; Teplinsky E; Chandarlapaty S; Solit D; Cadoo K; Speyer J; D'Andrea G; Adams S; Patil S; Haque S; O'Neill T; Friedman K; Esteva FJ; Hudis C; Modi S
    Breast Cancer Res; 2017 Aug; 19(1):89. PubMed ID: 28764748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G).
    Miura Y; Sukawa Y; Hironaka S; Mori M; Nishikawa K; Tokunaga S; Okuda H; Sakamoto T; Taku K; Nishikawa K; Moriwaki T; Negoro Y; Kimura Y; Uchino K; Shinozaki K; Shinozaki H; Musha N; Yoshiyama H; Tsuda T; Miyata Y; Sugimoto N; Shirakawa T; Ito M; Yonesaka K; Yoshimura K; Boku N; Nosho K; Takano T; Hyodo I
    Gastric Cancer; 2018 Jan; 21(1):84-95. PubMed ID: 28497176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
    Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
    J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial.
    Inoue K; Ninomiya J; Saito T; Okubo K; Nakakuma T; Yamada H; Kimizuka K; Higuchi T;
    Invest New Drugs; 2019 Jun; 37(3):538-547. PubMed ID: 30848403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab With S-1 Plus Cisplatin in HER2-positive Advanced Gastric Cancer Without Measurable Lesions: OGSG 1202.
    Endo S; Kurokawa Y; Gamoh M; Kimura Y; Matsuyama J; Taniguchi H; Takeno A; Kawabata R; Kawada J; Masuzawa T; Yamamoto K; Kobayashi K; Sakai D; Shimokawa T; Satoh T
    Anticancer Res; 2019 Feb; 39(2):1059-1065. PubMed ID: 30711995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).
    Chia S; Bedard PL; Hilton J; Amir E; Gelmon K; Goodwin R; Villa D; Cabanero M; Tu D; Tsao M; Seymour L
    Oncologist; 2019 Nov; 24(11):1439-1445. PubMed ID: 31420468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer.
    Takahari D; Chin K; Ishizuka N; Takashima A; Minashi K; Kadowaki S; Nishina T; Nakajima TE; Amagai K; Machida N; Goto M; Taku K; Wakatsuki T; Shoji H; Hironaka S; Boku N; Yamaguchi K
    Gastric Cancer; 2019 Nov; 22(6):1238-1246. PubMed ID: 31102009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.